To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 2
This profile is validated by 2 label.

Company

Triox Nano ltd

Triox Nano ltd_logo
32
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Triox Nano developed a breakthrough disruptive technology for delivery of APIs to their target cells based on a patented S.M.A.R.T “Stimuli Responsive” nano machine technology. Our platform is based on a combination of MSNP + DNA molecular machines

Jerusalem, Center, Israel

Send a message

English

Triox Nano ltd

English

Triox Nano developed and patented a breakthrough disruptive technology for delivery of APIs to their target cells based on a patented S.M.A.R.T “Stimuli Multi Adjusted Responsive Technology” nano machinery technology. Our platform is based on a combination of MSNP + DNA molecular machines or other smart caps which enable preprogramming of the capping mechanism to react to a combination of variables. 

We chose to start with an indication called...

See more

Triox Nano developed and patented a breakthrough disruptive technology for delivery of APIs to their target cells based on a patented S.M.A.R.T “Stimuli Multi Adjusted Responsive Technology” nano machinery technology. Our platform is based on a combination of MSNP + DNA molecular machines or other smart caps which enable preprogramming of the capping mechanism to react to a combination of variables. 

We chose to start with an indication called TNBC(Triple Negative Breast Cancer) which has a great unmet need 

In vitro testing show up to 50 times greater efficacy in TNBC compared to Doxil(liposomal doxorubicin) and enter healthy cells 3 times less. 

In Vivo testing with over 200 animals show a 10-20 times stronger histologic result per molecule compared to Liposomal doxorubicin (Doxil, Caelyx) allowing us to give 25% of the Doxil dose and get up to 4 time better gamma-h2ax results.

We had just received an approval of our PCT in Europe. WO 2014087410 A1 ABSTRACT Recognition-release nanoporous substrate comprising active agents, methods of their preparation and uses.

No other company can utilize this synergistic combination of DNA MM and MSNP.

Our IP is very strong as we invented this field of science our approved PCT patent claims that any porous particle capped by at least one nucleic acid sequence and the agent is released by a triggered reaction of said capping sequence with at least one analyte (biomarker) thereby allowing said capping to be cleaved from said pore.

 

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

European Innovation Council - Accelerator beneficiaries
This label is a guarantee for investors to discover selected companies benefiting from Business acceleration services provided by the European Commission.
167 Entities
Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1481 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members
Access2EIC
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2140 Members